CRBU Stock Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
Caribou Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.67|
|52 Week High||US$32.65|
|52 Week Low||US$6.41|
|1 Month Change||18.80%|
|3 Month Change||-14.95%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.75%|
Recent News & Updates
Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders, because the company has just released...
Caribou Biosciences: Selling Close To Cash Balance
Today, we put developmental biotech company Caribou Biosciences in the spotlight for the first time. This nascent gene editing concern has fallen deep in 'Busted IPO' as any enthusiasm on the biotech sector has faded substantially in recent quarters. The stock now sells for near the cash on its balance sheet. Time to buy the dip? A full investment analysis follows in the paragraphs below.
|CRBU||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how CRBU performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CRBU performed against the US Market.
|CRBU Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CRBU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CRBU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors.
Caribou Biosciences Fundamentals Summary
|CRBU fundamental statistics|
Is CRBU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRBU income statement (TTM)|
|Cost of Revenue||US$56.01m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.20|
|Net Profit Margin||-682.39%|
How did CRBU perform over the long term?See historical performance and comparison
Is Caribou Biosciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: CRBU is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CRBU is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRBU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRBU is overvalued based on its PB Ratio (1.6x) compared to the US Biotechs industry average (1.4x).
How is Caribou Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBU's revenue (32.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CRBU's revenue (32.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRBU is forecast to be unprofitable in 3 years.
How has Caribou Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CRBU is currently unprofitable.
Growing Profit Margin: CRBU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRBU's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRBU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CRBU has a negative Return on Equity (-19.59%), as it is currently unprofitable.
How is Caribou Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRBU's short term assets ($368.0M) exceed its short term liabilities ($26.7M).
Long Term Liabilities: CRBU's short term assets ($368.0M) exceed its long term liabilities ($47.5M).
Debt to Equity History and Analysis
Debt Level: CRBU is debt free.
Reducing Debt: CRBU had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CRBU has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 35.9% each year.
What is Caribou Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRBU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRBU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRBU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRBU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRBU has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rachel Haurwitz (35 yo)
Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She serves as an Independent Director at Seer, Inc since November 08, 2021...
CEO Compensation Analysis
Compensation vs Market: Rachel's total compensation ($USD6.25M) is above average for companies of similar size in the US market ($USD2.62M).
Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.
Experienced Management: CRBU's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: CRBU's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CRBU only recently listed within the past 12 months.
Caribou Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Caribou Biosciences, Inc.
- Ticker: CRBU
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$591.271m
- Shares outstanding: 60.71m
- Website: https://cariboubio.com
Number of Employees
- Caribou Biosciences, Inc.
- 2929 7th Street
- Suite 105
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.